PCG
KPTI icon

Private Capital Group’s Karyopharm Therapeutics KPTI Stock Holding History

Private Capital Group’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-67
Closed -$6K – 2140
2021
Q3 		$6K Hold
67
– – ﹤0.01% 1521
2021
Q2 		$10K Hold
67
– – ﹤0.01% 1334
2021
Q1 		$11K Hold
67
– – ﹤0.01% 1263
2020
Q4 		$16K Hold
67
– – ﹤0.01% 1269
2020
Q3 		$15K Hold
67
– – ﹤0.01% 1188
2020
Q2 		$19K Buy
67
+30
+81% +$8.87K ﹤0.01% 1120
2020
Q1 		$11K Hold
37
– – ﹤0.01% 1244
2019
Q4 		$10K Buy
+37
New +$8.03K ﹤0.01% 1332

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Private Capital Group's KPTI Position: Q4 2021 in Review

Private Capital Group sold out of Karyopharm Therapeutics (KPTI) in Q4 2021, closing a stake of 67 shares — an estimated $6K sold.

Private Capital Group first reported a position in KPTI in Q4 2019 and held it in 8 quarters. The position peaked at $19K in Q2 2020. 143 funds tracked by Wall St. Rank hold KPTI as of Q4 2021.

  • Private Capital Group reported no remaining Karyopharm Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Private Capital Group sold 67 Karyopharm Therapeutics shares in Q4 2021, an estimated $6K.
  • Private Capital Group first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 8 quarters.
  • Private Capital Group's Karyopharm Therapeutics position peaked at $19K in Q2 2020.
  • 143 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2021.

Based on Private Capital Group's 13F filing for Q4 2021, filed 24 Jan 2022.